Skip to content

L’Union des Fédérations d’Apiculture de Wallonie et Bruxelles

UFAWB, honey ELISA residu testing, Quantichome

Menu
  • Home
  • Product
  • paraffin Liquid
  • Distributors
  • Blog
Menu
Biocredit Rapigen One Step Rapid Test

Biocredit Covid-19 Ag Detection Kit

Posted on November 27, 2021 by Beau

Qualitative

VITROS SARS CoV2 antigen assay – Procedural Steps: –

Stage 1: Nasopharyngeal swab specimen assortment:
1. Purchase a nasopharyngeal swab specimen by inserting the sterile swab into the nostril.
2. Push the sterile swab until resistance is met on the stage of the turbinate.
3. Rotate the sterile swab plenty of events in direction of the nasopharyngeal wall & go away throughout the place for
10 seconds to saturate the swab tip.
4. Take away the swab from the nostril fastidiously.
5. Place the swab specimen into the viral transport medium buffer tube and shut the tube tightly.
6. Transport the swab sample in VTM to the laboratory in a cold chain.
7. The sample may very well be saved in Room temperature (Beneath 30◦C) for as a lot as 24 hrs from the time of
sample assortment or at 2 – 8◦C for as a lot as 48 hrs from the time of sample assortment.

Diagnostics

1. The VITROS SARS CoV2 Antigen assay is a chemiluminescent immunoassay meant for the qualitative
detection of SARS-CoV-2 nucleocapsid antigens in nasopharyngeal (NP) specimens from individuals who
are suspected of COVID-19 inside one to five days of the onset of indicators, or mid-turbinate specimens
collected from asymptomatic individuals.
2. The assay must be carried out in VITROS 3600 Immunodiagnostics system or VITROS 5600 / VITROS XT 7600
Constructed-in system from Ortho.

Features

COVID-19, Nasopharyngeal swabs

 

SKU:G61RHA20

AVAILABILITY:In Stock with The Lowest Value throughout the Market

SHIPMENT:Related Day Cargo Orders Sooner than 14

H00SIZE:20 Exams/KitSPECIFICITY:98.90%

Type

Immunochromatography speedy verify

Description

Lateral motion immunochromatographic assay that adopted twin color system.
For the qualitative detection of SARS-CoV-2 antigen from nasopharyngeal swab specimen.
The verify incorporates colloid gold conjugate pad and a membrane strip pre-coated with antibodies specific to SARS-CoV-2 antigen on the verify traces (T).
A visible black band (antibody-antigen-antibody gold conjugate sophisticated) appears on the verify traces (T) If SARS-CoV-2 antigen is present throughout the specimen.
The administration line (C) reveals that verify is carried out appropriately.
Evaluated with panel specimen (n = 75) by PCR
Sensitivity: 90,2 %
Specificity: 100 %

 

Biocredit Antigen Test
Biocredit Antigen Test

Guidance for use of VITROS SARS CoV2 Antigen CLIA based Examine from Ortho Medical

Calibration Differ

 

Stage 2: Sample preparation for testing:

1. Sample preparation should be carried out in BSL-2 stage cabinet throughout the Laboratory.
2. Mix the swab specimen in VTM tube properly (vortex roughly 3-5 seconds).
3. Change 100 μL VITROS SARS-CoV-2 Antigen Extraction Buffer proper right into a labelled new sample tube.
4. Add 400 μL viral sample to the above tube (to deal with 1:4 ratio of extraction buffer: sample)
5. Mix properly (Cap/Plug the sample tube and vortex roughly 3-5 seconds).

Biocredit Covid-19 Ag Detection Kit

G61RHA20 RapiGEN 20 test cards (pkg)
EUR 95

Panbio™ COVID-19 Ag Rapid Test Device

41FK10 Abbott 25 Tests/Kit
EUR 96

Panbio™ COVID-19 Ag Rapid Test Device (Nasal)

41FK11 Abbott 25 Tests/Kit
EUR 95
Description: The Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 is a β -coronavirus, which is an enveloped non-segmented positive-sense RNA virus 2. It is spread by human-to-human transmission via droplets or direct contact, and infection has been estimated to have a mean incubation period of 6.4 days and a basic reproduction number of 2.24-3.58. Among patients with pneumonia caused by SARS-CoV-2, fever was the most common symptom, followed by cough3. The main IVD assays used for COVID-19 employ real-time reverse transcriptase-polymerase chain reaction (RT-PCR) that takes a few hours 4. The availability of a cost-effective, rapid point- of-care diagnostic test is critical to enable healthcare professionals to aid in the diagnosis of patients and prevent further spread of the virus5. Antigen tests will play a critical role in the fight against COVID-19

COVID-19 IgG & IgM antibody

GEN-50001-50tests Ring Bio 50 tests
EUR 324
Description: A rapid test for detection of antibodies (IgG and IgM) for 2019-nCoV, the novel Coronavirus from the Wuhan strain. The test is easy to perform, takes 10 minutes to provide reliable results and is higly specific to the 2019-nCoV Coronavirus.

COVID-19 IgG/IgM Rapid Test Kit

UNCOV-20 UnScience 20T/kit
EUR 155
Description: COVID-19 IgG/IgM Rapid Test (Serum/Plasma/Whole Blood) is a qualitative membrane-based immunoassay for the detection of COVID-19 antibodies in serum, plasma, or whole blood. This test consists of two test lines, an IgG line and an IgM line, which is pre-coated with two mouse anti-human monoclonal antibodies separately. During testing, the sample reacts with COVID-19 antigen-coated on conjugated pad. As the complex continues to travel up the strip, the anti-COVID-19 IgM antibodies are bound on the IgM line, and the anti-COVID-19 IgG antibodies are bound on the IgG line. The control(C)line appears when sample has flowed through the strip. The presence of anti-COVID-19 IgM and/or IgG will be indicated by a visible test line in the IgM and IgG region. To serve as a procedural control, the control line should always appear if the test procedure is performed properly and the reagents are working as intended.

SARS-CoV-2 (COVID-19) Spike Antibody

3525-002mg ProSci 0.02 mg
EUR 171.82
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike Antibody

3525-01mg ProSci 0.1 mg
EUR 436.42
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Envelope Antibody

3531-002mg ProSci 0.02 mg
EUR 171.82
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Envelope protein is a small polypeptide that contains at least one alpha-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication (3).

SARS-CoV-2 (COVID-19) Envelope Antibody

3531-01mg ProSci 0.1 mg
EUR 436.42
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Envelope protein is a small polypeptide that contains at least one alpha-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication (3).

SARS-CoV-2 (COVID-19) NSP7 Peptide

9155P ProSci 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP7 Peptide

SARS-CoV-2 (COVID-19) Membrane Peptide

9157P ProSci 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) Membrane Peptide

SARS-CoV-2 (COVID-19) NSP8 Peptide

9159P ProSci 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP8 Peptide

SARS-CoV-2 (COVID-19) NSP9 Peptide

9161P ProSci 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP9 Peptide

SARS-CoV-2 (COVID-19) NSP9 Peptide

9163P ProSci 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP9 Peptide

SARS-CoV-2 (COVID-19) Membrane Peptide

9165P ProSci 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) Membrane Peptide

SARS-CoV-2 (COVID-19) NSP8 Peptide

9167P ProSci 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP8 Peptide

SARS-CoV-2 (COVID-19) Envelope Peptide

9169P ProSci 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) Envelope Peptide

SARS-CoV-2 (COVID-19) NSP2 Peptide

9171P ProSci 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP2 Peptide

SARS-CoV-2 (COVID-19) NSP2 Peptide

9173P ProSci 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP2 Peptide

SARS-CoV-2 (COVID-19) NSP4 Peptide

9175P ProSci 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP4 Peptide

SARS-CoV-2 (COVID-19) NSP6 Peptide

9177P ProSci 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP6 Peptide

SARS-CoV-2 (COVID-19) NSP10 Peptide

9179P ProSci 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP10 Peptide

SARS-CoV-2 (COVID-19) ORF6 Peptide

9189P ProSci 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF6 Peptide

SARS-CoV-2 (COVID-19) ORF9b Peptide

9191P ProSci 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF9b Peptide

SARS-CoV-2 (COVID-19) ORF3a Peptide

9275P ProSci 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF3a Peptide

SARS-CoV-2 (COVID-19) ORF3b Peptide

9277P ProSci 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF3b Peptide
×

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent Posts

  • VivaDiag SARS-CoV-2 Ag Rapid Test
  • SBI Lentiviral Technologies pGF2 mcmv
  • Biocredit Covid-19 Ag Detection Kit
  • Rabbit Interleukin Human Interleukin 17 ELISA Bundle
  • qpcr retrovirus Virus Titration Kits

Recent Comments

    Archives

    • November 2021
    • July 2021
    • May 2021

    Categories

    • antibody purchase
    • Bicistronic Vector
    • biot transfection
    • Blog
    • cd22 antibodies
    • cd8 antibody
    • chromogranin a antibody
    • Cloning Service
    • crispr cas9 antibody
    • cytotoxicity assay kit
    • gfp western blot
    • hmgb1 elisa kit
    • il 22 antibody
    • Product
    • triglyceride assay
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    © 2022 L’Union des Fédérations d’Apiculture de Wallonie et Bruxelles | Powered by Superbs Personal Blog theme